Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Tumor buster - where will the CAR-T cell therapy ‘missile’ go?
Chunrun Qu, Hao Zhang, Hui Cao, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 45

Showing 26-50 of 45 citing articles:

Novel CAR‐T Cells Specifically Targeting SIA‐CIgG Demonstrate Effective Antitumor Efficacy in Bladder Cancer
Mengting Ding, Jiaxing Lin, Caipeng Qin, et al.
Advanced Science (2024) Vol. 11, Iss. 40
Open Access | Times Cited: 3
Therapeutic targets of armored chimeric antigen receptor T cells navigating the tumor microenvironment
Xianjun Li, Tianjun Chen, Xuehan Li, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 3
The enchanting canvas of CAR technology: Unveiling its wonders in non-neoplastic diseases
Jinhui Shu, Wei Xie, Zhaozhao Chen, et al.
Med (2024) Vol. 5, Iss. 6, pp. 495-529
Open Access | Times Cited: 2
The Potential Impact of New Drug and Therapeutic Modalities on Drug Resistance to Renal Cell Carcinoma
Pedro Caetano-Pinto
Anticancer Research (2023) Vol. 43, Iss. 3, pp. 983-991
Open Access | Times Cited: 5
Mitochondrial dynamics in pulmonary disease: Implications for the potential therapeutics
Hui Li, Xinyan Dai, Jun-Fu Zhou, et al.
Journal of Cellular Physiology (2024) Vol. 239, Iss. 11
Closed Access | Times Cited: 1
Harnessing cytokines to optimize chimeric antigen receptor-T cell therapy for gastric cancer: Current advances and innovative strategies
Zewei Cheng, Xiaohan Cui, Song Li, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 178, pp. 117229-117229
Open Access | Times Cited: 1
EphA2 specific chimeric antigen receptor engineered T cells for the treatment of prostate cancer
Miaomiao Zhang, Hai‐Ting Wang, Meng Wang, et al.
Translational Oncology (2024) Vol. 50, pp. 102111-102111
Open Access | Times Cited: 1
Chimeric Antigen Receptor T Cell Therapy in Acute Myeloid Leukemia: Trials and Tribulations
Swati Garg, Wei Ni, James D. Griffin, et al.
Hematology Reports (2023) Vol. 15, Iss. 4, pp. 608-626
Open Access | Times Cited: 3
Antigen processing and presentation‐related signature‐derived BNIP3 is a novel oncogene and immunotherapy determinant in osteosarcoma based on machine learning and in vitro validation
Yang Chen, Yajie Cao, Song Wu, et al.
The Journal of Gene Medicine (2023) Vol. 26, Iss. 1
Open Access | Times Cited: 2
Immunoengineering via Chimeric Antigen Receptor-T Cell Therapy: Reprogramming Nanodrug Delivery
Theodora Katopodi, Savvas Petanidis, Doxakis Anestakis, et al.
Pharmaceutics (2023) Vol. 15, Iss. 10, pp. 2458-2458
Open Access | Times Cited: 2
The expanded application of CAR-T cell therapy for the treatment of multiple non-tumoral diseases
Zhuoqun Liu, Yuchen Xiao, Jianjun Lyu, et al.
Protein & Cell (2023) Vol. 15, Iss. 9, pp. 633-641
Open Access | Times Cited: 2
Les cellules CAR-T anti-CD19: prototypes du médicament vivant1
Michel Sadelain, Isabelle Rivière
Bulletin de l Académie Nationale de Médecine (2024) Vol. 208, Iss. 9, pp. 1288-1298
Closed Access
Efficacy and safety of novel multiple-chain DAP-CAR-T cells targeting mesothelin in ovarian cancer and mesothelioma: a single-arm, open-label and first-in-human study
Tongpeng Xu, Tian Tian, Chen Wang, et al.
Genome Medicine (2024) Vol. 16, Iss. 1
Open Access
Drug delivery for age-related bone diseases: From therapeutic targets to common and emerging therapeutic strategies
Jiaming Bi, Jiawei Zeng, Xiaohao Liu, et al.
Saudi Pharmaceutical Journal (2024) Vol. 32, Iss. 12, pp. 102209-102209
Open Access
CAR-T cell therapy: Challenge and opportunity for effective treatment of small cell lung cancer
Limei Yin, Ping Sun, Shujin Guo, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024), pp. 189228-189228
Closed Access
CAR-T immunotherapy - recent advances and current challenges in cancer treatment: a review.
Joanna Ronowicz
Acta Poloniae Pharmaceutica - Drug Research (2024) Vol. 81, Iss. 2, pp. 227-237
Open Access
Advancing Chimeric Antigen Receptor T-Cell Therapy for Acute Myeloid Leukemia: Current Limitations and Emerging Strategies
Daniela Damiani, Mario Tiribelli
Pharmaceuticals (2024) Vol. 17, Iss. 12, pp. 1629-1629
Open Access
Long-Term Follow-Up of Third Generation Anti-CD30 CAR T-Cell Bridging Autologous HSCT Therapy in Relapsed/Refractory CD30+ Lymphomas: A Single-Arm, Multicentre, Phase 1-2 Trial
Xiangmin Wang, Qing Zhang, Xicheng Chen, et al.
(2024)
Closed Access
The immunotherapy advancement targeting malignant blastomas in early childhood
Bolun Zang, Luyue Ding, Linlin Liu, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access
Editorial: The interconnection between the tumor microenvironment and immunotherapy in brain tumors
Chunrun Qu, Longbo Zhang, Wen Cheng, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access
Previous Page - Page 2

Scroll to top